Using transduced PDCD10-knockdown and -overexpressing GBM cells, the present study provided strong evidence for a promising role of PDCD10 in governing the sensitivity of GBM cells during TMZ treatment and in promoting cell regrowth post-TMZ treatment, which are representative of chemo-resistance and tumor relapse in clinical settings, respectively. The gene discussed is PDCD10; the disease is glioblastoma.